The Journal of Emergency Medicine
Volume 36, Issue 4 , Pages 338-341 , May 2009

Trimethoprim/Sulfamethoxazole Resistance in Urinary Tract Infections

Presented as an oral abstract at the Third Mediterranean Emergency Medicine Congress, Nice, France, September 1–5, 2005.

Received 19 October 2006 ,Revised 13 March 2007 ,Accepted 9 August 2007.

References 

  1. Talan DA, Naber KG, Palou J, Elkharrat D. Extended-release ciprofloxacin (Cipro XR) for treatment of urinary tract infections. Int J Antimicrob Agents. 2004;23(Suppl 1):S54–S66
  2. Nicolle LE. Urinary tract infection: traditional pharmacologic therapies. Am J Med. 2002;113(Suppl 1A):35S–44S
  3. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women (Infectious Diseases Society of America (IDSA)). Clin Infect Dis. 1999;29:745–758
  4. Stratton C. Fluoroquinolone antibiotics: properties of the class and individual agents. Clin Ther. 1992;14:348–375
  5. Appelbaum PC, Hunter PA. The fluoroquinolone antibacterials: past, present and future perspective. Int J Antimicrob Agents. 2000;16:5–15
  6. Naber KG, Bergman B, Bishop MC, et al. EAU guidelines for the management of urinary and male genital tract infections (Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU)). Eur Urol. 2001;40:576–588
  7. Goettsch W, van Pelt W, Nagelkerke N, et al. Increasing resistance to fluoroquinolones in Escherichia coli from urinary tract infections in The Netherlands. J Antimicrob Chemother. 2000;46:223–228
  8. Hooton TM. Practice guidelines for urinary tract infection in the era of managed care. Int J Antimicrob Agents. 1999;11:241–245
  9. Hooton TM, Stamm WE. Diagnosis and treatment of uncomplicated urinary tract infection. Infect Dis Clin North Am. 1997;11:551–581
  10. Canbaz S, Peksen Y, Sunter AT, Leblebicioglu H, Sunbul M. Antibiotic prescribing and urinary tract infection. Int J Antimicrob Agents. 2002;20:407–411
  11. Karlowsky JA, Kelly LJ, Thornsberry C, et al. Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States (Tracking resistance in the United States today. The surveillance network). Int J Antimicrob Agents. 2002;19:21–31
  12. Olafsson M, Kristinsson KG, Sigurdsson JA. Urinary tract infections, antibiotic resistance and sales of antimicrobial drugs—an observational study of uncomplicated urinary tract infections in Icelandic women. Scand J Prim Health Care. 2000;18:35–38
  13. Musa-Aisien AS, Ibadin OM, Ukoh G. Prevalence and antimicrobial sensitivity pattern in urinary tract infection in febrile under-5s at a children's emergency unit in Nigeria. Ann Trop Pediatr. 2003;23:39–45
  14. Forrell DJ, Morrissey I, Rubeis D, Robbins M, Felmingham D. A UK multicentre study of the antimicrobial susceptibility of bacterial pathogens causing urinary tract infection. J Infect. 2003;46:94–100
  15. Turnidge J, Bell J, Biedenbach DJ, Jones RN. Pathogen occurence and antimicrobial resistance trends among urinary tract infection isolates in the Asia-Western Pacific Region: report from the SENTRY antimicrobial surveillance program 1998–1999. Int J Antimicrob Agents. 2002;20:10–17
  16. Kahlmeter G. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECOSENS Project. J Antimicrob Chemother. 2003;51:69–76
  17. Talan DA, Stamm WE, Hooton TM, et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women. JAMA. 2000;283:1583–1590

PII: S0736-4679(07)00833-5

doi: 10.1016/j.jemermed.2007.08.068

The Journal of Emergency Medicine
Volume 36, Issue 4 , Pages 338-341 , May 2009

Article Tools